Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-0610 in myelofibrosis with prior JAK inhibitor exposure
2018-000579-34Phase 2Unknown
- Sponsor
- Constellation Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pelabresib and ruxolitinib in myelofibrosis (MF), thrombocythemia and myeloproliferative disorder (MPD) (2 cohorts), sponsored by Constellation Pharmaceuticals. Status: unknown.
02
Drugs
pelabresibruxolitinib
03
Conditions
myelofibrosis (MF)thrombocythemiamyeloproliferative disorder (MPD)
Beyond the preview
Go deeper on 2018-000579-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000579-34.